Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Bayer AG    BAYN   DE000BAY0017

BAYER AG

(BAYN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Bayer : In Roundup case, U.S. judge cuts $2 billion verdict against Bayer to $86 million

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/26/2019 | 12:03pm EDT
FILE PHOTO: Monsanto Co's Roundup shown for sale in California

(Reuters) - A California judge on Thursday reduced a $2 billion (£1.6 billion) jury verdict, slashing the award for a couple who blamed Bayer AG glyphosate-based weed killer, Roundup, for their cancer to $86.7 million.

(Reuters) - A California judge on Thursday reduced a $2 billion (£1.6 billion) jury verdict, slashing the award for a couple who blamed Bayer AG glyphosate-based weed killer, Roundup, for their cancer to $86.7 million.

Superior Court Judge Winifred Smith of the California Superior Court in Oakland said the jury's billion-dollar punitive damage awards were excessive and unconstitutional, but rejected Bayer's request to strike the punitive award outright.

Under Smith's final order, California couple Alva and Alberta Pilliod would receive roughly $17 million in compensatory damages and $69 million in punitive damages, down from $55 million and $2 billion, respectively.

The plaintiffs still have to formally accept the reduced awards. Brent Wisner, a lawyer for the Pilliods, in a statement on Friday welcomed the decision.

"While we believe the reduction in damages does not fairly capture the pain and suffering experienced by Alva and Alberta, the overall result is a big win," Wisner said.

Bayer said in a statement on Thursday that Smith's decision to slash the award was a step in the right direction, but added it would file an appeal.

"We continue to believe that the verdict and damage awards are not supported by the evidence at trial and conflict with the extensive body of reliable science and conclusions of leading health regulators worldwide that confirms glyphosate-based herbicides can be used safely and that glyphosate is not carcinogenic," the company said.

Bayer faces Roundup cancer lawsuits by more than 13,400 plaintiffs across the United States. The German company bought Roundup maker Monsanto in a $63 billion deal last year, but its share price has since tumbled over the glyphosate litigation.

Plaintiffs allege Roundup causes non-Hodgkin's lymphoma and that Monsanto for decades tried to influence scientists and regulators to bury cancer evidence. Bayer denies those allegations.

The company had asked Smith to strike the punitive damages award in the Pilliods' case, arguing that hundreds of studies and assessments by regulators worldwide concluded the herbicide to be safe for human use.

But the judge in her Thursday order rejected those arguments.

"In this case there was clear and convincing evidence that Monsanto made efforts to impede, discourage, or distort scientific inquiry and the resulting science," Smith said.

Bayer to date has lost three U.S. jury trials in the Roundup litigation, with juries in California granting multimillion-dollar awards. It is appealing the decisions.

In August, the company is scheduled to face its first trial outside California at a courthouse in St. Louis, Missouri. Monsanto has recruited Missouri-based expert witnesses to make its case in a place where it has century-old roots but where juries often hit companies with huge damages.

(Reporting by Tina Bellon in New York; Editing by Lisa Shumaker and Matthew Lewis)

By Tina Bellon

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAYER AG
07/26BAYER : In Roundup case, U.S. judge cuts $2 billion verdict against Bayer to $86..
RE
07/26NEWS HIGHLIGHTS : Top Company News of the Day
DJ
07/26NEWS HIGHLIGHTS : Top Company News of the Day
DJ
07/26NEWS HIGHLIGHTS : Top Company News of the Day
DJ
07/26NEWS HIGHLIGHTS : Top Company News of the Day
DJ
07/25BAYER : Roundup Verdict Cut From $2 Billion to $86.7 Million
DJ
07/25Bayer CropScience Limited reports Q1 results for FY 2019-20
AQ
07/23BAYER AKTIENGESELLSCHAFT : Preliminary announcement of the publication of financ..
EQ
07/22BAYER : Iberogast Drug Is Safe
DJ
07/22BAYER : sells Dr. Scholl's foot care business to Boston firm
AQ
More news
Financials (EUR)
Sales 2019 46 303 M
EBIT 2019 8 749 M
Net income 2019 3 447 M
Debt 2019 37 554 M
Yield 2019 4,76%
P/E ratio 2019 17,4x
P/E ratio 2020 12,6x
EV / Sales2019 2,02x
EV / Sales2020 1,91x
Capitalization 55 869 M
Chart BAYER AG
Duration : Period :
Bayer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 77,72  €
Last Close Price 59,91  €
Spread / Highest target 105%
Spread / Average Target 29,7%
Spread / Lowest Target -35,3%
EPS Revisions
Managers
NameTitle
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Wolfgang U. Nickl Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
Sector and Competitors
1st jan.Capitalization (M$)
BAYER AG-1.09%62 125
JOHNSON & JOHNSON1.60%347 095
PFIZER-2.25%239 227
ROCHE HOLDING LTD.8.61%232 404
ROCHE HOLDING10.69%232 404
NOVARTIS23.06%213 301